Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

The primary purpose of the study is to evaluate the effectiveness of zanzalintinib in combination with pembrolizumab as first-line maintenance therapy in participants with metastatic squamous NSCLC.

Trial Details

NCT ID
NCT07845786
Phase
PHASE2
Sponsor
Exelixis
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Carboplatin
  • Paclitaxel
  • Nab-paclitaxel
  • Pembrolizumab
  • Zanzalintinib
Locations (sample)
  • Omaha, Nebraska, United States|41.25626,-95.94043

Key Eligibility Criteria

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Life expectancy of ≥ 6 months.
  • Stage IV squamous NSCLC as defined by American Joint Committee on Cancer (AJCC) 9th Edition.
  • Measurable disease according to RECIST v1.1 as determined by the investigator and documented prior to starting induction therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →